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Profound immunosuppression (e.g., AIDS, transplant therapy) is epidemiologically associated with an
increased cancer risk, and often with oncogenic viruses. It is currently unclear how broadly this asso-
ciation translates to therapeutics that modulate immunity. A workshop co-sponsored by the FDA and
HESI examined how perturbing the immune system may contribute to carcinogenesis, and highlighted
priorities for improving non-clinical risk assessment of targeted immunomodulatory therapies. Con-
clusions from the workshop were as follows. 1) While profound altered immunity can promote tumor-
igenesis, not all components of the immune system are equally important in defense against or
promotion of cancer and a similar cancer risk for all immunomodulatory molecules should not be
assumed. 2) Rodent carcinogenicity studies have limitations and are generally not reliable predictors of
cancer risk associated with immunosuppression. 3) Cancer risk needs to be evaluated based on
mechanism-based weight-of-evidence, including data from immune function tests most relevant to
tumor immunosurveillance or promotion. 4) Information from nonclinical experiments, clinical epide-
miology and immunomodulatory therapeutics show that immunosurveillance involves a complex
network of cells and mediators. To support a weight-of-evidence approach, an increased focus on un-
derstanding the quantitative relationship between changes in relevant immune function tests and cancer
risk is needed.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Disclaimers
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1. Introduction
Patients, physicians, regulatory authorities, and the pharma-
ceutical industry all struggle with the challenge of assessing the
potential carcinogenic risks associated with the use of therapeuticsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(referred to as “immunomodulators” in this manuscript) and un-
derstanding their impact, if any, on tumor development and
growth. This could lead to a decision to not utilize a potentially life-
changing disease modifying agent due to concerns that the thera-
peutic could result in a future risk of cancer. A more complete
understanding of the risks of a speciﬁc drug could better inform
decisions regarding the choice of therapeutics for a given patient
and could ultimately result in better disease management,
enhanced monitoring for potential tumors, and increased ability to
interpret the relevance of early reports of human tumors poten-
tially associatedwith a speciﬁc therapeutic class of drugs or disease.
As limited long-term human data exist for a newly approved
therapeutic, one of the objectives of the nonclinical development
program is to characterize the carcinogenic risks of a product to
inform the clinical use of the drug, and communicate risk to the
prescriber and patient via product labeling. The carcinogenicity
assessment for any therapeutic is particularly challenging for
compounds that impact the function of the immune system. As a
result of a lack of availability of relevant data to inform risk, drug
product labels for immunomodulators frequently include the
statement that the impact of the therapeutic on the development of
tumors is not known, but that treatment with immunosuppres-
sants may result in an increased risk for malignancies. While such a
statement is notably based on the experience of transplant re-
cipients who received immunosuppressive therapy to maintain an
organ allograft, this may not be true for all immunomodulatory
therapeutics, and better methods to characterize and assess carci-
nogenic risk for these compounds is clearly needed.
By international agreement, drug products intended for chronic
or chronic-intermittent human use are required to be assessed for
their carcinogenic potential prior to marketing application (ICH,
1995). For small molecules, this has traditionally been completed
via either two life-time studies in rodents or via a single lifetime rat
study and a 6-month transgenic mouse model (ICH, 1997). For
biologic therapeutics, meaningful long-term studies in rodents are
frequently not possible due to immunogenicity or lack of adequate
cross-species pharmacodynamics (ICH, 2011). Nonetheless, a risk
assessment for carcinogenicity potential for biologic therapeutics is
still required. This assessment is generally based on a weight-of-
evidence evaluation that takes into consideration the target
biology and mechanism of action of the therapeutic, data from
chronic toxicology studies, published information such as data
from transgenic or knock-out animal models, human genetic dis-
eases, and previous human experience with similar molecules.
When this weight-of-evidence suggests a cause for concern, the
potential hazard can be addressed by product labeling. When there
are inadequate data to inform a product-speciﬁc assessment,
additional mechanistically focused studies may be completed to
better understand the risks of a therapeutic product.
Rodent lifetime carcinogenicity studies, which are commonly
conducted to support small molecule clinical development and
marketing applications, are used to help deﬁne the risk vs. beneﬁt
assessment and are summarized in product labeling information to
communicate this assessment to physicians and patients. Such
lifetime rodent studies have been able to detect many human
genotoxic carcinogens, and to date, there is no better-characterized
nonclinical model for risk assessment identiﬁed (Jacobs, 2006). In a
survey of the literature, Bugelski et al. (2010) found that various
rodent models, including 2-year carcinogenicity bioassays, are
unreliable predictors of human cancer risk associated with immu-
nosuppressive drugs (e.g, dexamethasone, prednisone, mycophe-
nolate, methotrexate, tacrolimus, everolimus). These ﬁndings cast
doubt on the predictive value of the 2-year carcinogenicity bioassay
for immunosuppressive agents.Given the clear challenge of assessing immunomodulatory
compounds for cancer risk, the U.S. Food and Drug Administration
(FDA) and the Health and Environmental Sciences (HESI) Immu-
notoxicology Technical Committee co-sponsored a public work-
shop in October of 2014 that was speciﬁcally intended to deﬁne
points to consider when building a product-speciﬁc weight-of-
evidence carcinogenicity assessment for either a small molecule or
a biologic therapeutic affecting immunity. The workshop gathered
together international leaders in the ﬁeld of oncology, tumor
development, and therapeutics from across industry, academia and
government in an attempt to provide diverse insights into the
mechanisms of tumor evolution and the impact of the immune
system on this complex process. The workshop was broken down
into four primary sessions to review the current knowledge on
human cancer risk associated with altered immunity and the
available models and tools to inform risk assessment. The ultimate
objectives were to identify knowledge gaps to guide future research
and to provide a framework to guide the development of product-
speciﬁc weight-of-evidence carcinogenicity risk assessments for
new immunomodulatory therapies. This manuscript presents
highlights from the workshop, synthesizes the learnings of the
organizing committee members into points to consider, and pro-
poses a framework for how to conduct a weight-of-evidence based
cancer risk assessment for immunomodulatory molecules.
2. Tumor necrosis factor (TNF) inhibitors and cancer risk
An introductory session was dedicated to TNF inhibitors
(referred to as anti-TNFs, including TNF receptor fusion protein
products), since experience with this class of marketed drugs il-
lustrates how it has been challenging to evaluate and then
communicate actual cancer risk for immunomodulators. In addi-
tion, the example of anti-TNFs is valuable given the plethora of
information relative to the biology of the TNF pathway and the
recent availability of human epidemiology data assessing the can-
cer risk associated with use of anti-TNFs. Overall, the data indicate
that elevated TNF is a risk factor for cancer, whereas its inhibition is
not generally associated with an increased cancer risk (Lebrec et al.,
2015). Based on extensive clinical data for this class of drugs, tar-
geted immunomodulation is not associated with the degree of
cancer risk associated with profound immunosuppression or
immunodeﬁciency.
The ﬁrst anti-TNFs reached the market in 1998 (Remicade®
[inﬂiximab]; Enbrel® [etanercept]). Currently, there are ﬁve anti-
TNF innovator molecules on the market (the three additional
ones are Humira® [adalimumamb], Cimzia® [certolizumab] and
Simponi® [golimumab]). The original inﬂiximab label and subse-
quent updates mentioned that patients with long duration of
Crohn's disease and chronic exposure to immunosuppressant
therapies are more prone to develop lymphomas. These labeling
updates were driven by case reports of lymphomas, hepatosplenic
T-cell lymphomas, skin cancers and Merkel cell carcinomas with
different anti-TNFs, early meta-analyses of controlled trials
(reviewed in Bongartz et al., 2006, 2009; Stone et al., 2006;
Bongartz et al., 2009; Pozadzides and Pro, 2009) and registry data
(Geborek et al., 2005; Wolfe and Michaud, 2007) that suggested an
increased risk. Similar labels and updates were applied to the
different anti-TNFs. However, themost recentmeta-analyses do not
indicate an overall increased cancer risk directly attributable to
anti-TNFs (Mercer et al., 2013; Solomon et al., 2014). It is recognized
that certain autoimmune diseases (e.g., rheumatoid arthritis) are
associated with an increased risk and that the risk correlates with
disease severity (Baecklund et al., 2006), which complicates the
interpretation of the epidemiology data.
A review of the TNF biology (Lebrec et al., 2015) indicates that
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(Carswell et al., 1975; Green et al., 1976), blocking the TNF pathway
can decrease tumor growth in rodents (Egberts et al., 2008). In
addition, TNF affects immune surveillance components both posi-
tively and negatively, depending on a broad array of contextual
signals, but does not appear to impact anti-Epstein Bar Virus (EBV)
immunity, which is often associated with lymphoma in immuno-
compromised patients (Miceli-Richard et al., 2009). Epidemiology
and genetic studies now indicate that TNF production and chronic
inﬂammation (discussed below) can promote tumor growth and
spread. In particular, TNF 308 A >G promoter region polymorphism
and increased TNF production are positively associated with
various malignancies (reviewed in Lebrec et al., 2015).
Overall, anti-TNFs illustrate how targeted immunomodulation is
not necessarily associated with the cancer risk that is typically
associated with profound immunosuppression or immunodeﬁ-
ciency, and how it is challenging to evaluate and communicate
cancer risk for immunomodulatory drugs with anti-inﬂammatory
properties in the absence of signiﬁcant amounts of clinical data.
3. Non-clinical and clinical evidence of a connection between
immunomodulation and cancer risk
To frame discussions that would occur later in the workshop on
patient immune status and cancer risk, several presentations
focused on human and animal data associating immune status with
cancer outcomes. Speciﬁcally, the presentations and discussion
included human data derived from patients with therapeutically-
induced, acquired or primary/congenital immunodeﬁciencies, pa-
tients with chronic inﬂammation or autoimmunity, immunopa-
thology evaluation of the tumormicroenvironment as a predictor of
patient survival, and emerging clinical outcomes in cancer patients
treated with various immunotherapies. The data in humans were
supplemented with a discussion of mechanistic studies in animal
models. Collectively, these data inform the current state of the
science regarding the interplay between immune system status and
cancer risk, and highlight speciﬁc immune system components as
positive or negative cancer risk factors.
3.1. Epidemiology
As detailed below, epidemiology data indicate that immuno-
suppression and chronic inﬂammation (e.g. autoimmune disease)
are both independently associated with increased cancer risk, and
in some circumstances, it is possible to have both. For example,
immunosuppression can give rise to chronic, unresolved infections
and inﬂammation that can independently increase cancer risk.
Immunosuppression, whether induced (therapeutic), acquired
(e.g., Human Immunodeﬁciency Virus/Acquired Immunodeﬁciency
Syndrome (HIV/AIDS)), or primary (i.e., genetic deﬁciency) is
associated with an increased risk of both virus-associated and non-
viral cancers. Increased cancer risks are typically identiﬁed by
disproportionality in speciﬁc cancers and increased incidence rates
when comparing immunosuppressed populations against the
general background population (without identiﬁed
immunosuppression).
Among transplant recipients who receive immunosuppressive
therapy to maintain an organ allograft, very high relative risks
(>20-fold) are observed for Kaposi's sarcoma, non-Hodgkin's lym-
phoma, and non-melanoma skin cancer, and high relative risks (>5-
fold) are found for melanoma, leukemia, hepatobiliary, cervical, and
kidney cancers (kidney cancers being mostly observed in kidney
transplant patients where underlying kidney disease may be
involved). Lower relative risks (>2-fold) are observed for more
common cancers (e.g., colon, breast, lung, stomach, esophagus,pancreas, ovary) as estimated using 2003e2007 age-adjusted SEER
US cancer statistics (Penn, 1999, 2000; Kasiske et al., 2004). The
cancer risk increases as early as within a year after immunosup-
pression for both virally and non-virally associated cancers (Kasiske
et al., 2004); these data suggest a role for normal immunity in
controlling sub-clinical tumors.
The proﬁle of cancer risks seen amongst patients with HIV/AIDS
is generally similar to that seen in patients undergoing therapeutic
immunosuppression for organ transplantation, with increasing risk
as the patient progresses from HIV to AIDS (Grulich et al., 2007;
Engels et al., 2008). However, there are notable exceptions where
the risk in HIV patients is higher (e.g., central nervous system
lymphoma, non-Hodgkin's lymphoma and Kaposi's sarcoma) or
lower (e.g., cervical cancer) than the risk in transplant patients
(Grulich et al., 2007).
Interpreting data on cancer risk in individuals with primary
immunodeﬁciencies can be challenging due to the rarity of in-
dividuals with the speciﬁc condition. However, the data indicate
distinct cancer risk proﬁles for speciﬁc immune deﬁciencies. Very
high increased risk of non-Hodgkin's lymphomas, in some cases
>100-fold over the general population, is observed for various
primary immunodeﬁciencies, and these cancers typically occur
very early in life (in some cases with median age of onsets of less
than 2 years) and are usually EBV-negative (Gompels et al., 2003;
Cunningham-Rundles et al., 2002). In some cases it is difﬁcult to
assign causality of increased cancer risk in primary immune de-
ﬁciencies because they can occur with concomitant defects in non-
immune functions. For example, individuals with ataxia-
telangiectasia not only have deﬁciencies in T and B cell pop-
ulations, but also are susceptible to DNA damage due to a deﬁciency
in DNA repair (Celiksoy et al., 2014).
Chronic immune activation is an independent risk factor for
cancer, and can occur secondary to unresolved pathogenic infection
or autoimmunity; both chronic infection and autoimmunity are
increased in patients with congenital immune deﬁciencies. In such
cases, chronic B cell stimulation can contribute to a very high risk of
lymphoma development in these patients (Kuppers, 2005). Addi-
tionally, for some patients with a congenital immune deﬁciency,
the inability to clear pathogenic infections can lead to chronic
inﬂammation around the site of infection, and increase the risk of
site-speciﬁc cancers (e.g., gastric or oral cancers) (Kalha and Sellin,
2004; Uittamo et al., 2009).
The role of oncogenic viruses (i.e., viruses linked to cancer
development) in driving increased cancer risk with immunosup-
pression is complex and because viruses demonstrate species-
speciﬁc tropisms, the translation of mechanisms and models
across species is inherently challenging. A near universal associa-
tion between viral infection and cancer in humans has been iden-
tiﬁed for relatively few cancers, such as for cervical cancer and
human papilloma virus (HPV) (Bosch et al., 2002), Kaposi's sarcoma
and human herpes virus-8 (HHV-8) (Ablashi et al., 2002), and adult
T cell leukemia/lymphoma and human T lymphotropic virus-1
(Nicot, 2005). In contrast, whereas EBV is associated with lym-
phoma, not all lymphomas are caused by EBV. For example, lym-
phomas in most patients with congenital immunodeﬁciencies or
lymphomas that develop after more than one year of immuno-
suppression following organ transplantation are generally EBV-
negative. Additionally, the risk of EBV-negative lymphoma is
increased with various forms of chronic inﬂammation, including
autoimmunity (Ponce et al., 2014). These data demonstrate that a
viral etiology for lymphoma should not necessarily be presumed.-
While chronic infection with hepatitis B virus or hepatitis C virus is
a well recognized risk factor for liver cirrhosis and hepatocellular
carcinoma (Perz et al., 2006), the contribution of these viruses to
the increased incidence of liver cancer in patients with HIV/AIDS is
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Overall, these data illustrate how T cell deﬁciency is associated
with speciﬁc virally-induced tumors. Of note, increased incidences
of virus induced neoplasia in mice (e.g., lymphoma due to murine
leukemia virus and mammary tumors due to mouse mammary
tumor virus) (Reilly et al., 2005), and/or in macaques (e.g. lym-
phoma associated with lymphocryptoovirus (LCV)) (FDA, 2002;
Hutto, 2010), have been observed in preclinical studies with some
immunosuppressive agents but have not always translated to
elevated incidences of virally-induced neoplasia in humans
(Thomas et al., 2000; Weinblatt et al., 2014).
3.2. Evidence of key immune functions in human tumor
surveillance
The relationship between certain immune cells and human
cancer outcomes is being assessed through systems biology ap-
proaches. For example, large-scale investigations of inﬁltrating
immune cells in the tumor microenvironment and their relation-
ship with patient outcomes have shown robust correlations be-
tween speciﬁc immune cells and long-term survival (Pages et al.,
2005).
In the case of colorectal cancer, characterization of the types of
inﬁltrating lymphocytes and their location/density in the tumor
was a stronger predictor of patient outcome than traditional his-
topathological staging of disease (Galon et al., 2006). Of particular
importance is the presence of cytotoxic T-lymphocytes (CTLs;
CD3þ, CD8þ) and effector memory (CD45ROþ) T cells in the center
of tumors as a predictor of positive outcome. In contrast, tumor
associated helper T-cells (TH) TH17, regulatory T-cells, and TH2 cells
have a more variable role in patient outcomes depending on the
cancer type (Pages et al., 2005; Galon et al., 2006). This research has
resulted in the development of the “Immunoscore,” which char-
acterizes the presence of inﬁltrating immune cells in the tumor
microenvironment as a prognostic indicator of patient outcome; an
international effort is currently ongoing to validate the “Immuno-
score” across a range of human cancers (Galon et al., 2014).
A longitudinal study of 3625 subjects showed that low natural
cytotoxicity (i.e. natural killer (NK) activity against the K562 cell
line) was associated with increased incidence of cancer over time
(Imai et al., 2000). There is also a positive correlation between the
NKG2D ligand expression on tumor cells and survival of patients
with primary colorectal carcinoma tumors, emphasizing the
contribution of NK cells in the control of certain tumors (McGilvray
et al., 2009). Human natural killer cell deﬁciencies have also been
associated with virally-related tumors (reviewed in Orange, 2013).
Therapeutic efﬁcacy in the area of immuno-oncology, including
the cell-based prostate cancer immunotherapy Provenge®, the
CTLA-4 checkpoint inhibitor Yervoy®, the programmed cell death
protein 1 (PD-1) checkpoint inhibitors Keytruda® and Opdivo®, and
the bispeciﬁc CD19-directed CD3 T-cell engager Blincyto® conﬁrm
the importance of adaptive immunity in control of human cancer.
Taken as a whole, the clinical and epidemiologic information
demonstrate a strong relationship between speciﬁc components of
the immune system and the control of developing and established
tumors. Such data provide insight into key immune components
involved in the control of tumorigenesis that could be evaluated in
the context of cancer risk assessment.
3.3. Four general paradigms underlie the mechanistic relationship
between the immune system and cancer
The relationship between the host immune system and cancer is
complex, dynamic, and contextual. It is complex in that many
different factors, derived from normal as well as transformed cells,participate in shaping the response towards tumor tolerance or
inhibition. It is dynamic in that the composition of cellular and
soluble factors, as well as the tumor and immune response itself,
evolve over time. It is contextual in that the different components
of the immune system underlie long-term survival across differing
tumor types. Such complexities challenge easy generalizations
when describing (or predicting) the risk of cancer associated with
immunomodulation.
Four general mechanisms have been proposed to explain the
inter-relationship between the immune system and cancer: tumor
immunoediting, oncogenic viruses, chronic inﬂammation, and
chronic B cell stimulation.
Tumor immunoediting is a dynamic process wherein the tumor
evolves under the selective pressure of the immune response,
while the immune system continues to adapt to the evolving tu-
mor. It involves both innate and adaptive immune cells in concert
with key cytokines and mediators can, in some cases, protect the
host from tumors (Dunn et al., 2002; Vesely et al., 2011). In some
cases the immune response may be subverted or inadequate to
suppress the development of clinical disease (e.g., as a conse-
quence of PDL1 being expressed on tumor cells), and a dynamic
equilibrium is established. Studies of immunoediting in mice
identiﬁed central immune participants in host defense against
tumors, including NK cells, dendritic cells, CTL, and NKT cells in
concert with key cytokines and mediators (e.g., interferon [IFN]-a,
perforin, granzymes).
Oncogenic viruses can transform infected cells. Among identiﬁed
oncogenic viruses, a highly increased risk of cancer is observed
among immunosuppressed patients infected with Kaposi's sar-
coma virus (HHV-8), EBV, or HPV. These viruses transform infected
cells by disrupting the cell-cycle regulatory control, and in the
context of therapeutically-induced immune suppression, virus-
related cancer risk is thought to closely correlate with cumulative
exposure to immunosuppressive drugs (Piselli et al., 2013). Simi-
larly, the risk of oncogenic-virus mediated cancers increase as
HIV þ patients progress to AIDS (Engels et al., 2008). Protective
anti-viral immunity is mediated by both innate (e.g., NK, NKT,
dendritic cells and granulocytes) and adaptive (e.g., CTL) cells,
which can suppress or clear virus/virally infected cells, produce
pro-inﬂammatory cytokines (e.g., interleukin [IL]-12, IL-18, IFN-g,
and IL-6, TNF-a), and promote the cellular production of IFN-a,
which both directly interferes with viral replication and promotes
antiviral immunity (Biron and Brossay, 2001; Guidotti and Chisari,
2001; Malmgaard, 2004).
Chronic inﬂammation can contribute to tumor development and
growth through a number of mechanisms, including tumor initia-
tion (arising from associated reactive oxygen- and nitrogen-
mediated DNA damage) and tumor promotion (wherein cytokines
and inﬂammatory mediators can facilitate tumor growth and me-
tastases, angiogenesis, increased cell survival, reduced cell death
and altered differentiation) (Coussens and Werb, 2002; de Visser
et al., 2005; Federico et al., 2007; Mantovani et al., 2008).
Chronic B cell stimulationmayarise fromunderlying disease (e.g.,
autoimmunity, EBV infection) or from unresolved infection which
may be secondary to immune suppression. Under these circum-
stances, B-cells may be driven into a proliferative response within
germinal centers; this state of genomic hyper-mutability coupled to
a high replication rate sets the stage for an increased risk for
acquiring critical errors in the genome that may result in lym-
phomagenic B-cell transformation (Kuppers, 2005).
These different mechanisms connecting the immune system to
tumorigenesis should be interrogated when prioritizing the
development of tools and approaches to conduct a cancer risk
assessment with immunomodulators.
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tumorigenicity with immunomodulatory pharmaceuticals:
points to consider
Immunomodulatory drugs have the potential to adversely
impact the control of oncogenic viruses and tumors. This is linked
to their mechanism of action, and there is a need to determine,
manage and communicate the relative risk to humans. Traditional
tools such as lifetime studies in rodents, while useful for genotoxic
compounds, are not reliable for assessment of carcinogenicity risk
with non-genotoxic immunosuppressive drugs to the authors’
knowledge. Other elements and approaches should be used to
inform risk even though there is no single model or immunological
endpoint recognized as predictive of human cancer risk.
Below are different proposed points to consider when building a
weight-of-evidence based cancer risk assessment for immuno-
modulators and a brief discussion of these points and existing
knowledge gaps.
Fig. 1 illustrates how the weight-of-evidence could be built
throughout the drug development process and combines nonclin-
ical and clinical information.
4.1. Evidence of nature and degree of impact on the immune system
While it is recognized that the interplay between immunity and
tumorigenesis is very complex and that different components of
the immune system are either pro- or anti-tumorigenic, the
epidemiology and mechanistic information presented above and
discussed at the workshop indicate that certain endpoints could
inform risk, including NK cell activity, T helper and cytotoxic T cell
functions (including endpoints relating to factors that govern
killing mechanisms such as activation and perforin/granzyme
production). Assessing the impact of a therapeutic on mechanisms
relating cancer and immunity during development of drug candi-
dates, while not part of standard toxicology studies, can be included
in nonclinical studies (including pharmacology studies) but may
also need to be evaluated in the context of clinical trials or as
speciﬁc mechanistic studies. For any risk assessment, it is critical to
note that the effects observed in nonclinical species do not neces-
sarily always translate to humans. For example, blocking IL-15 de-
pletes NK cells in mice and cynomolgus monkeys but not in
humans (Lebrec et al., 2013). Such data indicate that responses in
animal models should be interpreted with caution and illustrate
the value of obtaining supportive evidence of pathway integrity
between non-clinical species and humans to inform the interpre-
tation of the data. In some cases, there may not be a suitableFig. 1. Examples of elements that can inform cancer risk assessment for immunomodula
different stages (ﬁrst row), from discovery to marketing, different types of information (f
(immune function and safety monitoring) will have the most weight but will be available o
some immune function, the assessment should consider the breadth and depth of the effec
viruses.nonclinical species for predicting the human responses to inter-
vention in a pathway.
Because of the complex interplay between the immune system
and the multi-step process of tumorigenesis, there is a need to
further develop immune function assessment tools, notably in
humans (or with human tissues), to monitor functional immune
status and inform cancer risk.
4.2. Development of tumors in animal studies
Although rodent models are widely used to assess the carcino-
genicities of small molecule drugs and environmental agents, these
models were found to be unreliable predictors of cancer risk
associated with immunosuppressive agents in a recent review.
Bugelski et al. (2010) critically examined published studies that
used rodent models to assess the carcinogenicities of immuno-
suppressive agents. Themodels included two-year exposure assays,
neonatal mice, genetically engineered mice, UV/ionizing radiation/
chemical carcinogens (including two-stage initiation/promotion
protocols), viral tumorigenesis, and tumor transplantation systems
(allografts and xenografts). Immunosuppressive drugs were
selected based on their mechanisms of action (genotoxic and non-
genotoxic) and included agents known to increase cancer in
humans as well as agents not associated with increased human
cancer risk. The drugs evaluated included abatacept, azathioprine,
busulfan, cyclophosphamide, cyclosporine, dexamethasone, ever-
olimus, leﬂuomide, methotrexate, mycophenolate mofetil, predni-
sone, sirolimus and tacrolimus. Of these, only abatacept is a large-
molecule biotherapeutic.
Several conclusions were drawn from this critical analysis
(Bugelski et al., 2010). The two-year rodent bioassays (rats and
mice) favored detection of genotoxic carcinogens and complete
carcinogens (e.g., cyclophosphamide, azathioprine) and had a high
rate of both false-positive and false-negative results. Subsets of
these drugs were also tested in alternate animal models. The
neonatal mouse model, the transgenic Tg.AC (v-Ha-ras) and rasH2
mouse models, homozygous and heterozygous p53-deﬁcient
mouse models favored detection of genotoxic carcinogens and in
most cases did not demonstrate increases in tumor types relevant
to humans. Chemical carcinogenesis models of initiation and/or
promotion developed primarily to study pharmacological activity
of anti-tumor agents, when used to assess potential carcinogenicity
risk yielded variable results and, therefore, are not necessarily
reliable for this purpose. Ionizing radiation is itself immunosup-
pressive, making interpretation of drug effects problematic. Viral
tumor models (murine leukemia virus and murine mammarytors throughout the drug development process. As development progresses through
rom basic pharmacology to human epidemiology data) can inform risk. Human data
nly in the later stage of development. While all immunomodulatory agents will impact
ts of a given agent on known actors of immune surveillance of tumors and oncogenic
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relevant to humans. Implanted tumor models yielded inconsistent
results and again are likely better suited to screening potential anti-
tumor therapeutics rather than for risk assessment. In summary,
the two-year rodent bioassay and alternative models reviewed do
not seem to be useful for detecting risk of neoplasia with non-
genotoxic immunomodulatory therapeutics.
Lymphomas associated with lymphocryptovirus infection of
macaques may present an opportunistic model for EBV infection of
humans (Kawabata et al., 2011). However, the practicality for
intentional use of this as a prospective model is severely limited
due to the number of animals required to adequately power a study
and the difﬁculties inherent in establishing uniform LCV infections.
To reliably predict human responses to immunomodulators,
animal models must recapitulate key elements of human immune
surveillance. Foremost is tumor antigenicity. The mutational loads
and antigenicities of tumors generated in most rodent models are
largely uncharacterized and may fall below a threshold needed to
generate neoantigens for immune detection/activation
(Schumacher and Schreiber, 2015). Recent studies of immune
checkpoint inhibitors (anti- CTLA-4 and PD-1/PD-Ligand 1 anti-
bodies) indicate that these therapies are most effective against
melanomas and other cancers with high mutation frequencies
(“mutators”) (Le et al., 2015; Schumacher and Schreiber, 2015). The
high mutational load in these tumors increases the likelihood of
generating tumor-speciﬁc neoantigens that can be recognized by
endogenous tumoricidal lymphocytes (Schumacher and Schreiber,
2015). Mouse models known to generate antigenic tumors that
are subject to immune surveillance include methylcholanthrene-
induced sarcomas (Vesely et al., 2011; Mittal et al., 2014) and
genetically induced lung and pancreatic adenocarcinomas (Garbe
et al., 2006; DuPage et al., 2011; 2012; DuPage and Jacks, 2013).
Mice defective inmismatch repair or DNA polymerase proofreading
are also attractive models for assessing the impact of immuno-
modulators on cancer risk, since these mice are strong mutators
that spontaneously develop a range of tumor types at high fre-
quencies (Albertson et al., 2009; Preston et al., 2010). Recent studies
of human colorectal and endometrial cancers with defects in
mismatch repair or proofreading indicate that these mutator-
driven tumors are immunogenic (Le et al., 2015; van Gool et al.,
2015).
Another obvious key element of predicting impaired tumor
immunosurveillance in people is overcoming species differences in
immunity. Species-speciﬁc effects of immunomodulators could
lead to false-positive or -negative results in rodents. Mice recon-
stituted with human immune components could help mitigate this
potential shortcoming (Brehm et al., 2014; Fujiwara et al., 2015;
Gujer et al., 2015). These “humanized mice” may prove to be use-
ful models of EBV-induced lymphoproliferative disease and lym-
phomas (Fujiwara et al., 2015; Gujer et al., 2015), which occur at
high frequency in immunosuppressed humans and are often
associated with EBV infection (Ponce et al., 2014). However, there
are limitations of humanized mouse models (Brehm et al., 2014),
such as inconsistent or incomplete immune reconstitution, that
may compromise their value in assessing the effects of immuno-
modulators on cancer risk.
Although it is tempting to continue developing new “improved”
rodent models, there is no guarantee that these will be any better
than currentmodels in predicting human cancer risk. The history of
these efforts suggests that eachmodel will carry its own limitations
which may be realized only after years of development and vali-
dation. The failure to date of rodent models to reliably predict the
risk of neoplasia with non-genotoxic immunomodulatory thera-
peutics presumably reﬂects intrinsic differences in rodent and
human biology. The pharmacological inactivity andimmunogenicity of most large-molecule biotherapeutics in rodents
is also a serious barrier to model development. However, nonclin-
ical models could still be useful if they provide insight into un-
derstanding the impact of a speciﬁc therapeutic on pathways
critical to immune-related carcinogenicity risk.
4.3. Development of tumors or evidence of viral activation in
clinical studies
Ultimately, human data will be most informative, including as-
sessments of imbalances in occurrence of speciﬁc tumor types and
of speciﬁc viral infection and/or reactivation. However, as demon-
strated by the case of anti-TNFs, an understanding of any potential
effect of the disease state and/or patient genetic background on
cancer incidence is critical to evaluate whether it could be
adversely affected by drug treatment. The challenge and a greatly
needed area of focus is the development of methods that would
allow for the early detection of evidence of increased neoplasm
during clinical development.
5. Regulatory aspect of the weight-of evidence approach
Recently, the requirement of lifetime rodent studies for all small
molecules has been questioned (Sistare et al., 2011). In an attempt
to ascertain if an alternative product-speciﬁc weight-of-evidence
carcinogenicity assessment for small molecules could reliably
replace at least one of the lifetime rodent studies in some instances,
the International Conference on Harmonization (ICH) Steering
Committee endorsed a proposal to consider modiﬁcation of the
current ICH S1 recommendation such that lifetime rodent studies
may not be automatically triggered for all relevant small molecules.
This approach would allow for a weight-of-evidence assessment
that takes into consideration the pharmacological proﬁle, the
genotoxicity proﬁle, data from chronic toxicology studies, and ev-
idence of hormonal and immune disruption to justify a plan to
address risk in lieu of the rat lifetime carcinogenicity study (ICH,
2012; FDA, 2013). Prior to any revisions to the current approach, a
prospective evaluation of the utility of the weight-of-evidence
approach is being undertaken (FDA, 2013). As the impact of a
therapeutic on the immune system is one aspect of this weight-of-
evidence approach, a clear understanding of the impact of a drug on
speciﬁc arms of immunity, and their relationship to tumor initia-
tion, growth, and development is essential.
Regardless of the approach taken to assess the carcinogenic risk
of a therapeutic product, clear communication of that risk to the
prescribing physicians and the patients who require treatment can
be an equally challenging task. The risks of a drug product are
described in the approved drug product labeling. In the U.S., in-
formation on the potential carcinogenic risk of any drug product
can be found in several locations in the approved drug labeling
depending on the strength of the data suggesting risk, as outlined
in the regulatory requirements for labeling. If human data sug-
gesting risk exists, this information can be found in Section 6
Adverse Events, Section 5 Warnings and Precautions, or in a
boxedwarning, depending on the strength of the data. Data derived
from animal studies are presented in Section 13.1 under the
heading “carcinogenesis”. Of note, the regulations require that
Section 13.1 “… must state whether long term studies in animals
have been performed to evaluate carcinogenic potential and, if so,
the species and results. … Any precautionary statement … must
include practical, relevant advice to the prescriber on the signiﬁ-
cance of these animal ﬁndings. Human data suggesting that the
drug may be carcinogenic … as described in the ‘Warnings and
Precautions’ section, must not be included in this subsection of the
labeling.”
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from lifetime rodent studies such as data on immune functions
known to be critical for tumor surveillance would be incorporated
in labels if seen as informative to the prescriber.
The risk assessment for immunomodulatory compounds re-
quires a detailed understanding of the diverse and complex
mechanisms of spontaneous tumor development, the ability for the
body's defense systems to detect and eliminate any aberrant cells,
and the net impact of the therapeutic on each of the inter-related
processes. The assessment must also take into consideration the
role of the underlying disease which can also inﬂuence tumor
initiation, growth, escape, and metastasis.
Fig. 2 illustrates how an immunotoxicology-centered weight-of-
evidence carcinogenicity assessment could be conducted for im-
munomodulators and how such information could inform labels.
6. Looking towards the future
Discussions held at the HESI-FDA workshop and among the
authors during manuscript preparation demonstrate a growing
consensus around the role of speciﬁc immune cells in host pro-
tection against cancer (e.g., dendritic cell, T cells, NK cells). This
conﬁdence is based on ﬁndings from human genetic deﬁciencies,
animal models, clinical experience with therapeutic immunomo-
dulation and review of tumor biopsy data and survival outcomes in
cancer patients. However, what is less clear is the relationship be-
tween degree of alteration (either quantitative or functional) in
immune endpoints and cancer risk. Such limitations hinder our
ability to translate in vivo/ex vivo/in vitro assay data on speciﬁc
immune function endpoints into statements about cancer risk, and
often result in broad generalizations about cancer hazard with
immune modulation. The uncertainty increases as we move from
broad spectrum immune suppression to more targeted immuneFig. 2. Cancer risk assessment for immunomodulators. The need for an immunotoxicology
investigational therapy on the immune system and should be developed on a case-by-case
bioassays will be conducted (e.g., for small molecules). However, because rodent bioassays
ulators, risk assessment needs to include an evaluation of the breadth and depth of the impac
relating cancer and immunity. Such elements should inform the need for further investigamodulation, as is often the case with newer therapeutics, where
less data are available regarding the role of more discrete arms of
immunity on host protection against (or promotion of) cancer. Our
future ability to make more deﬁnitive and discrete statements
about the risks of therapeutic immunomodulation will continue to
rely on the collection of high quality mechanistic, clinical and
epidemiological data on cancer risks with speciﬁc immunomodu-
lators, as has been the case over the last decade with the TNF in-
hibitors. Newer mechanistic and clinical approaches along with
reﬁned understanding of the cellular and molecular basis of im-
munity using systems immunology approaches will also facilitate
our ability to assess cancer risk with immune modulation in the
future (Kidd et al., 2014).
7. Conclusions
The workshop presentations and discussions highlighted how
not all components of the immune system are equally important in
host defense towards cancer, how inﬂammation can promote
tumorigenesis as well as contribute to anti-tumor immunity, and
how a similar cancer risk should not be assumed for all immuno-
modulatory molecules. The case studies of anti-TNFs illustrated
difﬁculty in accurately evaluating such a risk even with a large
clinical data set and detailed knowledge of the mode of action.
Rodent studies, including carcinogenicity studies (i.e., two-year
bioassays) and different tumor models have limitations and are
not generally predictive of cancer risk associated with immuno-
modulators. Such studies should not be used as a single tool for risk
assessment purposes for immunomodulators; instead risk needs to
be evaluated based on weight-of-evidence including existing data
in the literature and targeted data generated from relevant immune
function tests (e.g., impact on effector memory T cells, cytotoxic T
cells, NK cells). For some of these endpoints, proper assays still needcentered assessment should be driven by the anticipated or unforseen impact of an
basis and in alignment with current regulatory expectations. In some instances, rodent
have limitations and are not necessarily informative for nongenotoxic immunomod-
t on the immune system in nonclinical and clinical studies with a focus on mechanisms
tions or monitoring.
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there is still limited understanding of the quantitative relationship
between changes in such endpoints and cancer risk. While the
value of certain tumor models needs to be further understood, an
increased focus on new approaches for monitoring immune func-
tion and early detection of cancer risk in humans was acknowl-
edged in the workshop. While potentially very challenging, there is
a need for better monitoring of immune function and pre-
neoplastic changes in humans that might better inform risk in
patients. Scientiﬁcally justiﬁed experimental approaches and re-
sults need to be part of weight-of-evidence based risk assessments
for proper evaluation by sponsors and regulators and proper
communication to prescribers and patients.
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